Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
- Conditions
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2019-05-03
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 15
- Registration Number
- NCT02080078
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 60
- Registration Number
- NCT02066038
Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Finnish Lung Cancer Group
- Target Recruit Count
- 18
- Registration Number
- NCT02064491
- Locations
- 🇫🇮
Pori Central Hospital, Pori, Finland
🇫🇮Helsinki University Hospital, Helsinki, Finland
🇫🇮Oulu University Hospital, Oulu, Finland
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
- Conditions
- Interventions
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02057380
- Locations
- 🇺🇸
Site US10004, La Jolla, California, United States
🇺🇸Site US10006, Tampa, Florida, United States
🇺🇸Site US10002, Baltimore, Maryland, United States
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
- Conditions
- Interventions
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02044601
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 267
- Registration Number
- NCT02039674
Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC
- Conditions
- Interventions
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT02037997
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2014-01-15
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT02036359
- Locations
- 🇨🇳
Department of Oncology, National Taiwan University Hospital, Taipei,, Taiwan
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02034097
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2016-03-29
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 250
- Registration Number
- NCT02031601
- Locations
- 🇨🇳
Yu Li, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.